Evolus
Evolus is the commercialization company behind Jeuveau in the United States and Nuceiva in several markets outside the United States. The product originates with Daewoong Pharmaceutical, which developed and manufactures the Nabota product family.
That division of roles is central to the company graph: Daewoong supplies the product and manufacturing identity, while Evolus holds important commercialization rights and presents the brand to aesthetic markets. The relationship does not make Nabota, Jeuveau, and Nuceiva one universal regulatory label.
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Evolus, Inc. |
| Base | United States |
| Website | evolus.com |
| Public status | Nasdaq-listed; ticker EOLS |
| Core toxin relationship | Commercialization of Jeuveau in the United States and Nuceiva in selected international markets |
| Product origin and manufacturing | Daewoong Pharmaceutical and its Nabota product family |
| Main brand node | Jeuveau / Nabota |
| Market focus | Self-pay aesthetic products rather than a broad therapeutic toxin franchise |
Daewoong Relationship
Section titled “Daewoong Relationship”Evolus licenses prabotulinumtoxinA-related rights from Daewoong and purchases Jeuveau from the Korean manufacturer. U.S. labeling identifies Jeuveau as prabotulinumtoxinA-xvfs and gives it a product-specific indication, potency assay, preparation, and safety framework.
Jeuveau is known as Nuceiva in several markets outside the United States. The shared commercial platform helps explain the names, but approval conditions, indications, presentations, and availability still depend on the local market.
Legal and Commercial History
Section titled “Legal and Commercial History”Daewoong, Evolus, Medytox, and AbbVie / Allergan were connected through a U.S. International Trade Commission dispute concerning botulinum toxin manufacturing-process trade secrets. Settlement agreements announced in 2021 removed important barriers to Evolus commercialization in its territories.
The dispute and settlements belong to ownership, licensing, and market-access history. They do not establish that Jeuveau, Nabota, Botox, or another toxin product is clinically superior, safer, stronger, longer-lasting, or unit-equivalent.
Market Interpretation
Section titled “Market Interpretation”Evolus is a useful example of a commercialization node that is distinct from a manufacturer. A reader following Jeuveau through the graph should be able to identify Evolus as the U.S. commercial company, Daewoong as the product-origin and manufacturing company, and the Jeuveau label as the controlling U.S. regulatory reference.